At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OS OneStream, Inc.
Not Yet Opened 09-19 16:00:00 EDT
30.65
-0.07
-0.23%
盘后30.65
+0.000.00%
18:08 EDT
High32.63Low30.57Vol284.31K
Open31.88D1 Closing30.72Amplitude6.71%
Mkt Cap4.91BTradable Cap762.05MTotal Shares160.31M
T/O8.88MT/O Rate1.14%Tradable Shares24.86M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
PR Newswire  ·  06:54
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
Press Release: MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
Dow Jones  ·  00:00
Press Release: MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Zacks  ·  09-19 22:21
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
PR Newswire  ·  09-19 19:00
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Benzinga  ·  09-19 02:45
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
Business Wire  ·  09-18 18:45
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
GlobeNewswire  ·  09-18 18:30
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
OneStream Unveils AI Anomaly Detection, Navigation Center
MT Newswires Live  ·  09-18 16:00
OneStream Unveils AI Anomaly Detection, Navigation Center
OneStream Builds on Applied Finance AI Solutions, Expands Innovations to Core Finance with OneStream Navigation Center and more
PR Newswire  ·  09-18 15:00
OneStream Builds on Applied Finance AI Solutions, Expands Innovations to Core Finance with OneStream Navigation Center and more
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
GlobeNewswire  ·  09-18 00:55
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
Zacks  ·  09-18 00:09
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
Rackspace Technology Announces Offer to Drive Rapid Migrations to AWS
GlobeNewswire  ·  09-18 00:00
Rackspace Technology Announces Offer to Drive Rapid Migrations to AWS
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
seekingalpha  ·  09-17 18:56
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
Business Wire  ·  09-17 18:00
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
OneStream Announces Timing of its Third Quarter Fiscal Year 2024 Financial Results Conference Call
PR Newswire  ·  09-17
OneStream Announces Timing of its Third Quarter Fiscal Year 2024 Financial Results Conference Call
AstraZeneca Imfinzi + Imjudo combo shows long-term liver cancer survival benefit
seekingalpha  ·  09-17
AstraZeneca Imfinzi + Imjudo combo shows long-term liver cancer survival benefit
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
Business Wire  ·  09-16
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
GlobeNewswire  ·  09-16
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
GlobeNewswire  ·  09-16
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
Business Wire  ·  09-16
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO

Introduction

Company Name.
OneStream, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--